Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates
August 04, 2022 16:01 ET
|
Iovance Biotherapeutics, Inc.
First Biologics License Application (BLA) Submission on Track in August 2022 SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage...
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
July 27, 2022 07:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 22, 2022 17:15 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 22, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 17, 2022 17:15 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors
June 13, 2022 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor...
Iovance Biotherapeutics to Present at Upcoming Conferences
June 08, 2022 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma
May 26, 2022 16:01 ET
|
Iovance Biotherapeutics, Inc.
Positive Results in Advanced Melanoma Patients, Including a 29% Objective Response Rate (ORR) in Cohort 4 of the C-144-01 Study Biologics License Application (BLA) Submission Planned for August 2022 ...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 20, 2022 17:15 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates
May 05, 2022 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor...
Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting
April 27, 2022 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...